scorecardresearchWhy Arihant Capital sees around 75% upside in this pharma stock

Why Arihant Capital sees around 75% upside in this pharma stock

Updated: 07 Jun 2022, 04:02 PM IST
TL;DR.
The brokerage has maintained its 'buy rating on Marksans Pharma with a target price of 80, which implies an upside of as much as 74 percent from its current market price of 46.
The brokerage has maintained its 'buy rating on Marksans Pharma with a target price of  <span class='webrupee'>₹</span>80, which implies an upside of as much as 74 percent from its current market price of  <span class='webrupee'>₹</span>46.

The brokerage has maintained its 'buy rating on Marksans Pharma with a target price of 80, which implies an upside of as much as 74 percent from its current market price of 46.